Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian
|
|
- Martha Dorsey
- 6 years ago
- Views:
Transcription
1 Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study René Thyrian German Center for Neurodegenerative Diseases (DZNE), site Rostock/Greifswald Institute for Community Medicine, Dept. Epidemiology of Health Care and Community Health, University Medicine Greifswald Ljubljana,
2 German Center for Neurodegenerative Diseases (DZNE) DZNE is a single entity existing at 9 different locations, where science is strategically aimed to find prevention and cures for neurodegenerative diseases. The aim is to identify new diagnostic markers and rapidly develop possible new therapies. To accomplish this, the DZNE follows an interdisciplinary research approach. Population Clinical Fundamental Health Care Research System Biomedicine Disease Modelling
3 GREIFSWALD
4 DelpHi-MV Dementia: life- and person-centered help in Mecklenburg-Western Pomerania GP-based cluster - randomised intervention trial to implement and evaluate an innovative concept of collaborative Dementia Care Management in Germany
5 DelpHi-MV: Design Intervention group GP practice patients 70 DemTect < 9 Patients home Baselineassessment Intervention Provision of Dementia Care Manager Patients home Follow-up assessment (annually) Inclusion of GP practices R Control group GP practice patients 70 DemTect< 9 pt. Patients home Baselineassessment care as usual Patients home Follow-up assessment (annually) Thyrian et al., Trials 2012
6 What happened so far approved by ethical commitee registration as clinical trial end of baseline recruitement baseline pilot main study follow-up 1 follow-up 2,3
7 DemTect - screening at GP practices primary care patients 70 years, living at home eligible: DemTect-score < 9 Informed consent of GP practices N=136 Patients screened ( 70 years, community-dwelling) N=6.838 patients at n=125 GP practices Eligible patients (DemTect < 9) n= patients (17.1%) at n=105 GP practices Informed consent n= 634 patients (54.4%) at n=95 GP practices Start Baseline assessment n=516 patients at n=94 GP practices Before baseline assessment Dead: n=19 Drop out: n= 99 - Withdrawal IC: n=85 - Moving away: n=5 - Others: n=9
8 DelpHi-MV: Instruments used for assessment Baseline Assessment SIDAM/SISCO: Severity grading of cognitive dysfunction: Structured Interview for the Diagnosis of Dementia B-ADL: Bayer Activities of Daily Living Scale GDS: Geriatric Depression Scale Qol-AD: Quality of Life - Alzeimer s Disease SF-12: 12-Item Short Form Health Survey (Health-related quality of life) STEP: Extract from Standardized Assessment of Elderly People in primary care (General state of health / Comorbidities) F-SozU: Fragebogen zur sozialen Unterstützung ICD-10 Diagnoses (Patient record ): Medical status Medication Assessment: drug intake, drug-related problems, potentially inadequate medications, adherence NPI: Neuropsychiatric Inventory (neuropsychiatric symptoms) RUD: Resource Utilization in Dementia (Informal care) BIZA-D: Berliner Inventar zur Angehörigenbelastung Demenz BSI: Brief Symptom Inventory PHQ-D: Patient Health Questionnaire Sociodemographic characteristics/social environment Informations about PwD Utilization of health care resources/social services/nursing aids Knowledge about dementia, treatment options and health care/social services In-depth assessment (Intervention) MMSE: MINI Mental State Exam (Cognitive performance) M.I.N.I. Depression: Mini International Neuropsychiatric Interview BESD: Beurteilung von Schmerzen bei Demenz CDR: Clinical Dementia Rating CareNapD: Care Needs Assessment for Dementia HABC: Healthy Age Brain Monitor (Caregiver Burden) Timed up & go: Restriction in mobility Tinetti-Test: Risk of falling Standard assessment conducted at each intervention visit (emergencies, state of health, medical consultations, hospitalisation, changes in medication, falls, pain, change in cognitive impairment, liquid intake, blood pressure, blood sugar) Neurological or psychiatric symptoms Suitability for rehabilitation Severity of dementia L
9 Background In Germany, the majority of PWD live at home Caregiving is provided predominantly by informal caregivers on a voluntary basis. Dementia caregiving leads to health and emotional consequences, including greater perceived stress, depression, social isolation, poor diet, diabetes, poor overall physical health etc
10 Special attention Neuropsychiatric symptoms in PWD have been found to be associated with distress of informal caregivers. i.e. angry behavior is associated with caregiver depression and apathy with a deterioration of the relationship between PWD and the caregiver Neuropsychiatric symptoms were identified as one common reason for the transition of PWD into nursing care. To delay institutionalization, early service utilization of PWD living in the community has been proven to be effective.
11 There have been studies before, but There is limited information about the relation between symptoms, their severity, and the amount of distress they impose on the caregiver. i.e. common or frequent symptoms are not necessarily the most distressing or most predictive for caregiver depression. There is a selection bias (formal diagnosis, specialists settings) Dementia is underdiagnosed in primary care, utilisation of services is low
12 Objectives (a) Examine different neuropsychiatric symptoms in persons screened positive for dementia in primary care with regard to their frequency, severity, and their impact on the distress of the caregiver (b) Compare persons with and without neuropsychiatric symptoms in regard to sociodemographics, carerelated, and disease-related variables (c) Identify variables related to the presence of neuropsychiatric symptoms that may serve as indicator or moderator variables and/or provide targets for interventions.
13 Behavioral and neuropsychiatric symptoms Neuropsychiatric inventory (NPI, Cummings, 1997) interview by proxy on 12 dimensions of neuropsychiatric behaviors ten behavioral and two neurovegetative dimensions 1. caregiver is asked a screening question whether or not the behavioral problem is present. 2. if yes, several subquestions are asked to explore the domain in more detail. 3. Caregiver is asked to rate the frequency [rarely (1) to very often (4)] and severity [mild (1) to severe (3)] of the most aberrant behavior. The product of both scores yields the NPI score for this domain (range 1-10) 3. Caregiver is asked to rate the distress associated with this domain with not at all (0) to very severely or extremely (5). A total NPI-score as well as a total distress score can be calculated by adding the scores of each domain into one total score and divide it by the number of domains.
14 Statistics 2 groups are of special interest the group without any neuropsychiatric symptoms, defined as having a NPI score = 0 the group with neuropsychiatric symptoms, being defined as having a NPI score = 1 in at least one of any of the twelve dimensions. Factors associated with NPI-scores are of interest: age, gender, cognitive impairment, ADL, formal diagnosis of dementia, gender of the caregiver, relationship, and living together as predictors. N=221 cases due to missing data in at least one of assessments Multivariate linear regression with fixed effects for the GPpractices
15 Results: the sample
16
17 Presence and frequency of neuropsychiatric symptoms
18 Thyrian et al, JAD 2015 Frequency of neuropsychiatric symptoms Appetite and Eating change Sleep and Night-time behavior change Aberrant motor behavior Apathy Euphoria Disinhibition Irritability Anxiety Dysphoria/Depression Agitation/Aggression Delusions Hallucinations 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% very often often sometimes rarely symptom not present caregiver distress in 12 dimensions of the NPI, m=6.11, SD=8.1 (range 0-49); PWD=persons with dementia
19 Severityof neuropsychiatric symptoms
20 Caregiver distress (NPI-12, when symptom present) Appetite and Eating change Sleep and Night-time behavior change Aberrant motor behavior Apathy Euphoria Disinhibition Irritability Anxiety Dysphoria/Depression Agitation/Aggression Delusions Hallucinations 0% 10% 20% 30% 40% 50% 60% 70% 80% 90%100% severely to extremely moderately minimal to mildly not at all caregiver distress in 12 dimensions of the NPI, m=6.11, SD=8.1 (range 0-49); PWD=persons with dementia Thyrian et al, JAD 2015
21 Factors associated with neuropsychiatric symptoms
22 Conclusions Every third person is affected by symptoms like depression, aggression, or irritability It is a clinically relevant issue in primary care The frequency and severity was rather low And, every 5 th caregiver did not indicate distress upon presence of symptom However, every third caregiver indicated severe distress when the symptom was delusions, aggression, depression, anxiety, and disinhibition ADL is associated to neuropsychiatric symptoms ADL might be a good intervention target
23 Limitations Cross-sectional analysis Association not prediction longitudinal data will follow in 2016 Limited generalisabilty and comparability Specific (understudied) sample of mild to moderately impaired PWD, symptoms are likely to increase in prevalence, severity, and consequential distress sample relevant to provide early and optimum care
24 Thank you for your attention!
25 some more reading! Eichler T*, Wucherer D, Thyrian J, et al. Antipsychotic drug treatment in ambulatory dementia care: prevalence and correlates. Journal of Alzheimers Disease 2015; 43(4): Eichler T*, Thyrian J, Dreier A, et al. Dementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial. International Psychogeriatrics. 2014; 26(2): Eichler T*, Thyrian J, Hertel J, et al. Rates of formal diagnosis in people screened positive for dementia in primary care: Results of the DelpHi-trial. Journal of Alzheimers Disease. 2014; 42(2): Fiß T*, Thyrian J*, Wucherer D, et al. Medication management for people with dementia in primary care: description of implementation in the DelpHi study. BMC Geriatrics. 2013; 13(1):121. Teipel S*, Thyrian J, Hertel J, et al. Neuropsychiatric Symptoms In Subjects Screened Positive For Dementia In Primary Care. International Psychogeriatrics 2015; 27(1): Thyrian J*, Eichler T, Hertel J, et al. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care results of the DelpHi-study. Journal of Alzheimers Disease 2015; Thyrian J*, Fiß T, Dreier A, et al. Dementia: Life- and personcentered help in Mecklenburg-Western Pomerania, Germany (DelpHi) study protocol for a randomised controlled trial. TRIALS 2012; 13(1):56. Wucherer D*, Eichler T, Kilimann I, et al. Antidementia drug treatment in people screened positive for dementia in primary care. Journal of Alzheimers Disease 2015; 44(3):
26 Antidementive drug treatment about 29% of patients screened positive for dementia received at least one antipsychotic drug 38% of these patients were not formally diagnosed with dementia Galantamine, n=8 (11.1%) Rivastigmine, n=10 (13.9%) 8.3% 2.8% 12.5% 1.4% PWD with formal diagnosis of dementia (ICD-10) PWD without formal diagnosis of dementia (ICD-10) Donepezil, n=22 (30.5%) 19.4% 11.1% 22.3% 22.3% Memantine, n=32 (44.5%) 62.5% 37.5% All antidementia drugs, n=72 (100%) % Wucherer et al., JAD 2015
27 Eichler et al., JAD 2015 Antipsychotic drug treatment about 10% of patients screened positive for dementia received at least one antipsychotic drug - typical antipsychotics: 36% - atypical antipsychotics: 64% Promethazine 3.5% Haloperidol 4.5% Typical antipsychotics Melperon 11% Pipamperon 18% Sulpirid Quetiapin 11% 21% Atypical antipsychotics Risperidon 32%
28 Association between medication use and NPI-scores Overall, antipsychotics use was significantly associated with higher total NPI scores Contrary to expectations, use of antipsychotics was associated with anxiety, apathy, disinhibition, aberrant motor behavior, In contrast overall antipsychotics use was not significantly associated with a clinically higher NPI scores in the dimensions of hallucinations or delusion Use of any antidepressant, sedative, antiepileptic, or antidementive drug or use of choline-esterase inhibitors was not associated with higher total NPI scores
29 Invitation for applications for the joint appointment of a professor (W3) at the Ernst-Moritz- Arndt-University Greifswald and the DZNE The DZNE (German Center for Neurogegenerative Diseases) in Rostock/ Greifswald and the Medical Faculty of the University of Greifswald are seeking to appoint an experienced researcher as soon as possible for the position of a Full professor (W3) in Health care research with a focus on neurodegenerative diseases.the site in Rostock/ Greifswald focuses on translating epidemiology of dementia care as well as clinical dementia research into primary care. Research areas covered at the site include clinical research, population-based clinical research, interventional health care research and analytical epidemiology/ translational research. The professorship will add epidemiological and methodological expertise with focus on neurodegenerative diseases. The successful candidate will have a professional background in one of following areas: epidemiology, neurology, psychology, psychiatry, geriatrics, social sciences or related areas and must provide a competitive record in the field of research and methods.the position offers a long term research perspective in clinical and epidemiological research in the field of neurodegenerative diseases. It is embedded in an international, multidisciplinary and highly competitive scientific environment.
30 THANK YOU
31
32 Caregiver distress (NPI-12, when symptom present)
33 Patient characteristics
34 Association with participant s characteristics Significant association between clinically relevant neuropsychiatric symptoms and resource utilisation/ caregiver distress, not quality of life; independent from age/ sex of Cognitive status contributes independently to the model Association was driven by the dimensions of: Agitation Apathy Irritability aberrant motor behavior, anxiety, appetite and eating changes
Neuropsychiatric symptoms in people screened positive for dementia in primary care
International Psychogeriatrics (2015), 27:1, 39 48 C International Psychogeriatric Association 2014 doi:10.1017/s1041610214001987 Neuropsychiatric symptoms in people screened positive for dementia in primary
More informationDementia care management: going new ways in ambulant dementia care within a GP-based randomized controlled intervention trial
International Psychogeriatrics (2014), 26:2, 247 256 C International Psychogeriatric Association 2013.The online version of this article is published within an Open Access environment subject to the conditions
More informationNEUROPSYCHOMETRIC TESTS
NEUROPSYCHOMETRIC TESTS CAMCOG It is the Cognitive section of Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) The measure assesses orientation, language, memory, praxis, attention, abstract
More informationNeuropsychiatric Inventory Nursing Home Version (NPI-NH)
This is a Sample version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) The full version of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) comes without sample watermark..
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationBehavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationScreening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationSupplementary Online Content
Supplementary Online Content Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized controlled trial. JAMA. doi:10.1001/jama.2014.93 eappendix.
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationResponsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease
ORIGINAL RESEARCH Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer s Disease Hadas Benhabib 1, Krista L. Lanctôt, PhD 1,2,4, Goran M. Eryavec, MD, FRCPC 3,4,
More informationBehavioural Problems and Patterns of Psychopharmacological Treatment given in Elderly Patients with Dementia
The International Journal of Indian Psychology ISSN 2348-5396 (e) ISSN: 2349-3429 (p) Volume 6, Issue 4, DIP: 18.01.090/20180604 DOI: 10.25215/0604.090 http://www.ijip.in October-December, 2018 Research
More informationNumber of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month
Part V: Specific Behavior Scales-Sleep Scales Based on past month First 4 items ask for time or amount of sleep 41. Pittsburgh Sleep Quality Index (PSQI) Sleep quality Sleep latency Sleep duration Habitual
More informationPhysical & Functional Assessments in Older Adults
Physical & Functional Assessments in Older Adults Scott Martin Vouri, PharmD, MSCI, BCPS, CGP, FASCP St. Louis College of Pharmacy Faculty Disclosure Dr. Vouri is funded by the Washington University Institute
More informationPsychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic
Original Articles 179 Psychiatric Morbidity in Dementia Patients in a Neurology-Based Memory Clinic Ching-Sen Shih 1, Sui-Hing Yan 2, Ying-Hoo Ho 1, Yuh-Te Lin 1, Jie-Yuan Li 1, and Yuk-Keung Lo 1 Abstract-
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationThe Neuropsychiatric Inventory Questionnaire: Background and Administration
The Neuropsychiatric Inventory Questionnaire: Background and Administration The Neuropsychiatric Inventory Questionnaire (NPI-Q) was developed and crossvalidated with the standard NPI to provide a brief
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationMental Health: Subjective evaluation of overall quality of life (QOL) Happiness, life satisfaction, morale, trait effect, etc. Quality of Life (QOL)
Mental Health: Subjective evaluation of overall quality of life (QOL) Happiness, life satisfaction, morale, trait effect, etc. Quality of Life (QOL) Multidimensional concept Includes: Physical health Cognitive
More informationRates of formal diagnosis of dementia in primary care: The effect of screening
Alzheimer s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 87 93 Cognitive & Behavioral Assessment Rates of formal diagnosis of dementia in primary care: The effect of screening Tilly
More informationKnown as both a thief and murderer,
&A Dementia Drugs: When Should They Be Stopped? Ron Keren, MD, FRCPC As presented at the University of Toronto s Primary Care Conference, Toronto, Ontario (May 25) Known as both a thief and murderer, Alzheimer
More informationComment on administration and scoring of the Neuropsychiatric Inventory in clinical trials
Alzheimer s & Dementia 4 (2008) 390 394 Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Donald J. Connor a, *, Marwan N. Sabbagh a, Jeffery L. Cummings b a Cleo
More informationNeuropsychiatric Syndromes
Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use
More informationA pan-european study on outcome measures for psychosocial intervention research in dementia
A pan-european study on outcome measures for psychosocial intervention research in dementia CHATTAT Rabih, MONIZ-COOK Esme, WOODS Bob, and members of the INTERDEM JPND outcomes working group 26 th Alzheimer
More informationQUESTIONNAIRE: Finland
QUESTIONNAIRE: Finland To put the assessment and management of behavioural disorders into a broader context of social and health policy and services in Finland, some background information is presented.
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationResearch Article Behavioural and Psychological Symptoms in Poststroke Vascular Cognitive Impairment
Behavioural Neurology, Article ID 430128, 5 pages http://dx.doi.org/10.1155/2014/430128 Research Article Behavioural and Psychological Symptoms in Poststroke Vascular Cognitive Impairment Meena Gupta,
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More informationIrene Røen 1*, Geir Selbæk 1,2,3, Øyvind Kirkevold 1,2,4, Knut Engedal 2, Ingelin Testad 5 and Sverre Bergh 1,2
Røen et al. BMC Health Services Research (2017) 17:365 DOI 10.1186/s12913-017-2289-x RESEARCH ARTICLE Resource Use and Disease Course in dementia - Nursing Home (REDIC-NH), a longitudinal cohort study;
More informationIntroduction. original article. Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender E-bPC
original article Camilla Callegari Ivano Caselli Marta Ielmini Simone Vender Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Insubria, Varese, Italy Influence of
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationScreening Summary (SS2)
15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More informationGetting To Know You UNEXPECTED OUTCOMES OF A MANDATED ASSESSMENT AND PLANNING PROCESS IN THE NSW HEALTH PATHWAYS TO COMMUNITY LIVING INITIATIVE (PCLI)
Getting To Know You UNEXPECTED OUTCOMES OF A MANDATED ASSESSMENT AND PLANNING PROCESS IN THE NSW HEALTH PATHWAYS TO COMMUNITY LIVING INITIATIVE (PCLI) What is the PCLI? NSW Government sponsored initiative:
More informationPediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline
Pediatric Primary Care Mental Health Specialist Certification Exam Detailed Content Outline Description of the Specialty The Pediatric Primary Care Mental Health Specialist (PMHS) builds upon the Advanced
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) FOCUSED QUESTION Is an individualized occupational therapy program more effective in modulating mood disturbances and functional deficits than general skills training for
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationAcetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia
STEER 2002; Vol 2: No.2 Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-alzheimer s dementia Bunmi Fajemisin Evidence search date: November 2001 www.signpoststeer.org
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationNIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28.
NIH Public Access Author Manuscript Published in final edited form as: Dement Geriatr Cogn Disord. 2012 ; 34(2): 96 111. doi:10.1159/000342119. Neuropsychiatric symptoms and global functional impairment
More informationReliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer s disease and their caregivers
International Psychogeriatrics (2008), 20:2, 383 393 C 2007 International Psychogeriatric Association doi:10.1017/s1041610207006254 Printed in the United Kingdom Reliability of the Brazilian Portuguese
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background
More informationLTC Research Influencing Practice
LTC Research Influencing Practice David A. Nace, MD, MPH Division of Geriatric Medicine naceda@upmc.edu PGS Clinical Update April 6, 2017 Conflicts of Interest Dr. Nace does not have any current conflicts
More informationSeverity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan
Original article Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan Si-Sheng Huang 1, Wen-Fu Wang 2, Yi-Cheng Liao 1 1 Department of
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationHow I Treat Aggression in Outpatients With Dementia. C. Omelan MD, FRCP(C)
How I Treat Aggression in Outpatients With Dementia C. Omelan MD, FRCP(C) Conflict of Interest I have no potential conflicts of interest to declare Overview Outline the prevalence of aggression Review
More informationThe Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias
The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias The Patient and Carers Perspective Mary-Frances Morris, Trustee, Alzheimer Scotland.
More informationIntroduction to Dementia: Complications
Introduction to Dementia: Complications Created in March 2005 Duration: about 15 minutes Axel Juan, MD The Geriatrics Institute axel.juan@med.va.gov 305-575-3388 Credits Principal medical contributor:
More informationRecognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
More informationThe course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric
More informationNeuropsychiatric Inventory - Nursing Home Version (NPI-NH)
Neuropsychiatric Inventory - Nursing Home Version (NPI-NH) Comprehensive Assessment of Psychopathology in Patients with Dementia Residing in Nursing Homes NPI - NH Neuropsychiatric Inventory Nursing Home
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationUnderstanding Dementia
Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive
More informationCOGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members
COGNOS Care for people with Cognitive dysfunction A National Observational Study Professor Dr Jan De Lepeleire COGNOS members Luxembourg Alzheimer Europe 2010 The Careplan in Belgium Requirements for reimbursement
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationA 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care
Helvik et al. BMC Geriatrics (2015) 15:47 DOI 10.1186/s12877-015-0047-7 RESEARCH ARTICLE Open Access A 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care
More informationResearch Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect of Apolipoprotein E ε4 Status
Behavioural Neurology Volume 2015, Article ID 275256, 6 pages http://dx.doi.org/10.1155/2015/275256 Research Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect
More informationCHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia. Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES
CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Dementia December 2010 Cynthia Boyd, MD, MPH* Bruce Leff, MD* Carlos
More informationDementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP
Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia
More informationBehavioral Issues in Dementia. March 27, 2014 Dylan Wint, M.D.
Behavioral Issues in Dementia March 27, 2014 Dylan Wint, M.D. OVERVIEW Key points Depression Definitions and detection Treatment Psychosis Definitions and detection Treatment Agitation SOME KEY POINTS
More informationLewy Body Disease. Dementia Education for the First Responder July 27, 2017
Lewy Body Disease Dementia Education for the First Responder July 27, 2017 Dylan Wint, M.D. NV Energy Chair for Brain Health Education Cleveland Clinic Lou Ruvo Center for Brain Health OUTLINE Lewy body
More informationAmerican Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline
American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline I. Geriatric Psychiatry Patient Care and Procedural Skills Core Competencies A. Geriatric psychiatrists shall
More informationMeasuring health-related quality of life in persons with dementia DOMS results & recommendations
Measuring health-related quality of life in persons with dementia DOMS results & recommendations Madeleine King, Siggi Zapart, Jan Sansoni, Nick Marosszeky On behalf of the Dementia Outcomes Measurement
More informationAntipsychotic Medication in Dementia; The good, the bad and the ugly! Anthony Bainbridge Deputy Director of Nursing Sheffield Health and Social Care
Antipsychotic Medication in Dementia; The good, the bad and the ugly! Anthony Bainbridge Deputy Director of Nursing Sheffield Health and Social Care Different types of antipsychotic medication Antipsychotic
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationDEMENTIA MEASURES GROUP OVERVIEW
DEMENTIA MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN DEMENTIA MEASURES GROUP: #47 Care Plan #280 Dementia: Staging of Dementia #281 Dementia: Cognitive Assessment
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationCentre for Research on Ageing [influencing policy improving practice enhancing quality of life]
Centre for Research on Ageing [influencing policy improving practice enhancing quality of life] Associate Professor Barbara Horner (PhD) Director, Centre for Research on Ageing, Faculty of Health Sciences.
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) Friedmann, E., Galik, E., Thomas, S. A, Hall, P. S, Chung, S. Y., & McCune, S. (2015). Evaluation of a pet-assisted living intervention for improving functional status
More informationNuplazid. Nuplazid (pimavanserin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.03 Subject: Nuplazid Page: 1 of 4 Last Review Date: June 22, 2018 Nuplazid Description Nuplazid (pimavanserin)
More informationDementia and Driving Checklist
6 Dementia and Driving Checklist 1. Questions to Ask the Patient and Family Patient Have you noticed any change or decreased confidence in your driving skills Have you had any accidents (or minor fender
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationK. Kahle-Wrobleski 1, J.S. Andrews 1, M. Belger 2, S. Gauthier 3, Y. Stern 4, D.M. Rentz 5, D. Galasko 6
The Journal of Prevention of Alzheimer s Disease - JPAD Volume 2, Number 2, 2015 Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer s Disease: Transforming Functional
More informationA 36-month follow-up of decline in activities of daily living in individuals receiving domiciliary care
BMC Geriatrics This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. A 36-month follow-up of decline
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationDEPRESSIVE SYMPTOMS IN ADULT CHILD CAREGIVERS OF VERY OLD MEXICAN AMERICANS: A STUDY OF THE HEPESE
DEPRESSIVE SYMPTOMS IN ADULT CHILD CAREGIVERS OF VERY OLD MEXICAN AMERICANS: A STUDY OF THE HEPESE David V. Flores, PhD, LMSW, MPH University of Texas Medical Branch Galveston UNIVERSITY OF SOUTHERN CALIFORNIA
More informationAntipsychotic Medications in the Treatment of Dementia with Behavior Disturbance
Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationThis information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.
Supporting people with dementia and their carers Information for the public Published: 1 November 2006 nice.org.uk About this information NICEclinicalguidelinesadvisetheNHSoncaringforpeoplewithspe cificconditionsordiseasesandthetreatmentstheyshouldreceive.
More informationHearn P, 2 Churchill B, and 2 Slaney H
Does a Dementia Unit Reduce Polypharmacy in a Veterans Pavilion? 1,3,4 Butler R, 1,2 Law R, 3 Coffey K, 3,4 Aubrey K, 3 Wicks C, Hearn P, 2 Churchill B, and 2 Slaney H 1 Discipline of Family Medicine -
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationSupplementary Online Content
Supplementary Online Content Atri A, Frölich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on in cognition in patients with Alzheimer disease: three randomized clinical
More information